Literature DB >> 16288214

Dual role of LOH at MMR loci in hereditary non-polyposis colorectal cancer?

A Sanchez de Abajo1, M de la Hoya, M van Puijenbroek, J Godino, E Díaz-Rubio, H Morreau, T Caldes.   

Abstract

hMLH1 and hMSH2 can be considered tumor suppressor genes, as both alleles must be inactivated in order to lose the mismatch repair (MMR) function. In this regard, it has been proposed that LOH at MMR loci is a common Knudson's second-hit mechanism in HNPCC patients. However, experimental evidence supporting this view is scarcely found in the literature. We have performed a comprehensive analysis of LOH in 45 HNPCC tumors carrying a germline alteration in MMR loci. Overall, we have detected LOH at MMR loci in 56% of the cases. However, up to 40% of the LOH events targeted the mutant allele, arguing against a second-hit role in these tumors. Interestingly, the age at diagnosis was significantly older in these patients. To explain this and previous data, we propose a dual role for LOH at MMR loci in HNPCC.

Entities:  

Mesh:

Year:  2006        PMID: 16288214     DOI: 10.1038/sj.onc.1209233

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  11 in total

1.  Functional interrogation of Lynch syndrome-associated MSH2 missense variants via CRISPR-Cas9 gene editing in human embryonic stem cells.

Authors:  Abhijit Rath; Akriti Mishra; Victoria Duque Ferreira; Chaoran Hu; Gregory Omerza; Kevin Kelly; Andrew Hesse; Honey V Reddi; James P Grady; Christopher D Heinen
Journal:  Hum Mutat       Date:  2019-08-17       Impact factor: 4.878

2.  Putative precursor cancer cells in human colorectal cancer tissue.

Authors:  Teodora E Goranova; Masayuki Ohue; Kikuya Kato
Journal:  Int J Clin Exp Pathol       Date:  2008-07-14

3.  Tumor characteristics as an analytic tool for classifying genetic variants of uncertain clinical significance.

Authors:  Robert M W Hofstra; Amanda B Spurdle; Diana Eccles; William D Foulkes; Niels de Wind; Nicoline Hoogerbrugge; Frans B L Hogervorst
Journal:  Hum Mutat       Date:  2008-11       Impact factor: 4.878

Review 4.  Promoter methylation in the genesis of gastrointestinal cancer.

Authors:  Clement Richard Boland; Sung Kwan Shin; Ajay Goel
Journal:  Yonsei Med J       Date:  2009-06-23       Impact factor: 2.759

5.  Refined mapping of loss of heterozygosity on 1q31.1-32.1 in sporadic colorectal carcinoma.

Authors:  Chong-Zhi Zhou; Guo-Qiang Qiu; Jun-Wei Fan; Xiao-Liang Wang; Hua-Mei Tang; Li Huang; Yu-Hao Sun; Zhi-Hai Peng
Journal:  World J Gastroenterol       Date:  2008-03-14       Impact factor: 5.742

6.  Genome-wide copy neutral LOH is infrequent in familial and sporadic microsatellite unstable carcinomas.

Authors:  Marjo van Puijenbroek; Anneke Middeldorp; Carli M J Tops; Ronald van Eijk; Heleen M van der Klift; Hans F A Vasen; Juul Th Wijnen; Frederik J Hes; Jan Oosting; Tom van Wezel; Hans Morreau
Journal:  Fam Cancer       Date:  2008-04-15       Impact factor: 2.375

7.  The onset of p53 loss of heterozygosity is differentially induced in various stem cell types and may involve the loss of either allele.

Authors:  Y Shetzer; S Kagan; G Koifman; R Sarig; I Kogan-Sakin; M Charni; T Kaufman; M Zapatka; A Molchadsky; N Rivlin; N Dinowitz; S Levin; G Landan; I Goldstein; N Goldfinger; D Pe'er; B Radlwimmer; P Lichter; V Rotter; R Aloni-Grinstein
Journal:  Cell Death Differ       Date:  2014-05-16       Impact factor: 15.828

Review 8.  Update on Lynch syndrome genomics.

Authors:  Päivi Peltomäki
Journal:  Fam Cancer       Date:  2016-07       Impact factor: 2.375

9.  Sequencing of Lynch syndrome tumors reveals the importance of epigenetic alterations.

Authors:  Noora Porkka; Satu Valo; Taina T Nieminen; Alisa Olkinuora; Satu Mäki-Nevala; Samuli Eldfors; Päivi Peltomäki
Journal:  Oncotarget       Date:  2017-11-14

10.  Partial loss of heterozygosity events at the mutated gene in tumors from MLH1/MSH2 large genomic rearrangement carriers.

Authors:  Katarina Zavodna; Tomas Krivulcik; Maria Gerykova Bujalkova; Tomas Slamka; David Martinicky; Denisa Ilencikova; Zdena Bartosova
Journal:  BMC Cancer       Date:  2009-11-20       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.